Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51393 | 0.92 | — | — | |
| SCHEMBL27887318 | 0.89 | TP53 (0.48) | EGFRTP53TAAR1CYP2A6LPL | |
| SCHEMBL1702558 | 0.86 | TP53 (0.56) | EGFRTP53UCHL1TAAR1HRH3 | |
| SCHEMBL2776957 | 0.86 | TP53 (0.56) | EGFRTP53UCHL1TAAR1HRH3 | |
| SCHEMBL6747631 | 0.80 | LPL (0.45) | HRH3LPLLIPGNISCHCA2 | |
| SCHEMBL19423242 | 0.78 | RXRA (0.48) | EGFRTP53UCHL1TAAR1HRH3 | |
| Ethylene SCHEMBL27468236 | 0.76 | TP53 (0.59) | TP53TAAR1CYP2A6LPLLIPG | |
| SCHEMBL36295 | 0.76 | TP53 (0.67) | TP53TAAR1CYP2A6LPLLIPG | |
| SCHEMBL403303 | 0.76 | TP53 (0.68) | TP53TAAR1CYP2A6ALDH1A1TSHR | |
| SCHEMBL2493917 | 0.76 | IDO1 (0.48) | EGFRTP53UCHL1TAAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102264357-B | Melanin production inhibitor | POLA CHEM IND INC | 2015-04-01 | — | — | CN | disclosed |
| CN-102264357-A | Melanin production inhibitor | — | 2011-11-30 | — | — | CN | disclosed |
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6699836-B2 | Vancomycin analogs | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-02 | — | — | US | disclosed |
| EP-0667353-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1016670-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6518243-B1 | Desleucyl glycopeptide antibiotics and methods of making same | TRUSTEES OF PRINCETON UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | disclosed |
| WO-2001081372-A2 | VANCOMYCIN ANALOGS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2001-11-01 | — | — | WO | disclosed |
| CN-1071334-C | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2001-09-19 | — | — | CN | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| CN-1119649-A | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 1996-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | FUT6, FUT5, ST6GAL1 | EGFR 790/4885TP53 2645/4885UCHL1 3664/4885 |
| US-20020042365-A1 | Vancomycin analogs | VNN1, PTMS, ASNS | EGFR 703/4885TP53 1743/4885UCHL1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.